Cargando…
Conditionally Reprogrammed Cells from Patient-Derived Xenograft to Model Neuroendocrine Prostate Cancer Development
Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. It develops mainly via NE transdifferentiation of prostate adenocarcinoma in response to androgen receptor (AR)-inhibition therapy. The study of NEPC development has been hampered by a lack of clinically relevant models. W...
Autores principales: | Ci, Xinpei, Hao, Jun, Dong, Xin, Xue, Hui, Wu, Rebecca, Choi, Stephen Yiu Chuen, Haegert, Anne M., Collins, Colin C., Liu, Xuefeng, Lin, Dong, Wang, Yuzhuo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7349646/ https://www.ncbi.nlm.nih.gov/pubmed/32512818 http://dx.doi.org/10.3390/cells9061398 |
Ejemplares similares
-
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer
por: Qu, Sifeng, et al.
Publicado: (2018) -
Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer
por: Choi, Stephen Yiu Chuen, et al.
Publicado: (2018) -
Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?
por: Lin, Dong, et al.
Publicado: (2016) -
Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014) -
ZRSR2 overexpression is a frequent and early event in castration-resistant prostate cancer development
por: He, Haiqing, et al.
Publicado: (2021)